Survey to Assess Why People Are Not Responding to Treatment in Hypertension

Bayer1,589 enrolled

Overview

This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients

Study Type

OBSERVATIONAL

Enrollment

1,589

Conditions

Arterial Hypertension

Interventions

Telmisartan (Kinzal/Pritor, BAY68-9291)DRUG

Patients under daily life treatment receiving Pritor according to local drug information.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men or women over 18 * Hypertensive patients * Uncontrolled hypertension (blood pressure \>/=140/90 mmHg on the day of consultation or \>/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure \>/=150 mmHg (in the absence of orthostatic hypotension) * Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ) * Patients examined in common medical care practice, whatever the reason for consultation * Patients informed of the study

Locations (1)

Unnamed facility

Many Locations, France

Outcomes

Primary Outcomes

Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic

Time frame: on day 1

Secondary Outcomes

Analyses of the factors that had an impact on the therapeutic decision

Time frame: on day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.